Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

155 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Neoadjuvant Nivolumab Plus Chemotherapy Followed By Response-Adaptive Therapy for HPV+ Oropharyngeal Cancer: OPTIMA II Phase 2 Open-Label Nonrandomized Clinical Trial.
Rosenberg AJ, Agrawal N, Juloori A, Cursio J, Gooi Z, Blair E, Chin J, Ginat D, Pasternak-Wise O, Hasina R, Starus A, Jones FS, Izumchenko E, MacCracken E, Wolk R, Cipriani N, Lingen MW, Pearson AT, Seiwert TY, Haraf DJ, Vokes EE. Rosenberg AJ, et al. Among authors: wolk r. JAMA Oncol. 2024 Jun 6:e241530. doi: 10.1001/jamaoncol.2024.1530. Online ahead of print. JAMA Oncol. 2024. PMID: 38842838
Correction to: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program.
King B, Soung J, Tziotzios C, Rudnicka L, Joly P, Gooderham M, Sinclair R, Mesinkovska NA, Paul C, Gong Y, Anway SD, Tran H, Wolk R, Zwillich SH, Lejeune A. King B, et al. Among authors: wolk r. Am J Clin Dermatol. 2024 May 24. doi: 10.1007/s40257-024-00864-1. Online ahead of print. Am J Clin Dermatol. 2024. PMID: 38789821 No abstract available.
The Epidemiology of Hospital-Treated Alopecia Areata in Denmark, 1995-2016.
Sørensen SBT, George P, Jagun O, Wolk R, Napatalung L, Zwillich SH, Iversen L, Ehrenstein V. Sørensen SBT, et al. Among authors: wolk r. Dermatol Ther (Heidelb). 2024 Apr;14(4):993-1006. doi: 10.1007/s13555-024-01145-9. Epub 2024 Apr 16. Dermatol Ther (Heidelb). 2024. PMID: 38625633 Free PMC article.
Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program.
King B, Soung J, Tziotzios C, Rudnicka L, Joly P, Gooderham M, Sinclair R, Mesinkovska NA, Paul C, Gong Y, Anway SD, Tran H, Wolk R, Zwillich SH, Lejeune A. King B, et al. Among authors: wolk r. Am J Clin Dermatol. 2024 Mar;25(2):299-314. doi: 10.1007/s40257-024-00846-3. Epub 2024 Jan 23. Am J Clin Dermatol. 2024. PMID: 38263353 Free PMC article. Clinical Trial.
Utilization of Rosuvastatin and Endogenous Biomarkers in Evaluating the Impact of Ritlecitinib on BCRP, OATP1B1, and OAT3 Transporter Activity.
Huh Y, Plotka A, Wei H, Kaplan J, Raha N, Towner J, Purohit VS, Dowty ME, Wolk R, Vourvahis M, King-Ahmad A, Mathialagan S, West MA, Lazzaro S, Ryu S, Rodrigues AD. Huh Y, et al. Among authors: wolk r. Pharm Res. 2023 Nov;40(11):2639-2651. doi: 10.1007/s11095-023-03564-3. Epub 2023 Aug 10. Pharm Res. 2023. PMID: 37561322 Free PMC article.
Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double-blind, placebo-controlled trial.
Hordinsky M, Hebert AA, Gooderham M, Kwon O, Murashkin N, Fang H, Harada K, Law E, Wajsbrot D, Takiya L, Zwillich SH, Wolk R, Tran H. Hordinsky M, et al. Among authors: wolk r. Pediatr Dermatol. 2023 Nov-Dec;40(6):1003-1009. doi: 10.1111/pde.15378. Epub 2023 Jul 17. Pediatr Dermatol. 2023. PMID: 37455588 Clinical Trial.
155 results